Immunicum AB has posted positive survival data from a Phase I/II study of the therapeutic cancer vaccine Intuvax for the treatment of metastatic renal cancer. The study, initiated in February 2012, includes a total of 12 patients, each treated with two intratumoral injections/vaccinations with Intuvax, two weeks apart, after which their cancer-affected kidney, as part of the standard treatment, was surgically removed. Vaccination with Intuvax did not have any negative impact on patients’ ...